361 related articles for article (PubMed ID: 18300756)
21. Older adults: should the paradigm shift from standard therapy?
Estey EH
Best Pract Res Clin Haematol; 2008 Mar; 21(1):61-6. PubMed ID: 18342813
[TBL] [Abstract][Full Text] [Related]
22. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
23. Impact of reinduction regimens on the clinical course of adult acute nonlymphocytic leukemia.
Welborn JL; Lewis JP; Meyers FJ
Leukemia; 1988 Nov; 2(11):711-6. PubMed ID: 3054348
[TBL] [Abstract][Full Text] [Related]
24. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
25. Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies.
Bertoli S; Tavitian S; Berard E; Gadaud N; Luquet I; Huynh A; Sarry A; Huguet F; Récher C
Leuk Lymphoma; 2019 Jan; 60(1):238-241. PubMed ID: 29893611
[No Abstract] [Full Text] [Related]
26. Laromustine (cloretazine).
Vey N; Giles F
Expert Opin Pharmacother; 2010 Mar; 11(4):657-67. PubMed ID: 20163276
[TBL] [Abstract][Full Text] [Related]
27. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
28. Approach to patients with primary refractory acute myeloid leukemia.
Orlowski RJ; Mangan JK; Luger SM
Curr Opin Hematol; 2015 Mar; 22(2):97-107. PubMed ID: 25575037
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of acute myeloid leukemia: current approaches.
Smits EL; Berneman ZN; Van Tendeloo VF
Oncologist; 2009 Mar; 14(3):240-52. PubMed ID: 19289488
[TBL] [Abstract][Full Text] [Related]
30. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
[TBL] [Abstract][Full Text] [Related]
31. New therapeutic strategies in acute lymphoblastic leukemia.
Jeha S
Semin Hematol; 2009 Jan; 46(1):76-88. PubMed ID: 19100370
[TBL] [Abstract][Full Text] [Related]
32. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology.
Brugières L; Pacquement H; Le Deley MC; Leverger G; Lutz P; Paillard C; Baruchel A; Frappaz D; Nelken B; Lamant L; Patte C
J Clin Oncol; 2009 Oct; 27(30):5056-61. PubMed ID: 19738127
[TBL] [Abstract][Full Text] [Related]
33. Is there a role for maintenance therapy in acute myeloid leukaemia?
Baer MR
Best Pract Res Clin Haematol; 2009 Dec; 22(4):517-21. PubMed ID: 19959102
[TBL] [Abstract][Full Text] [Related]
34. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
35. On the road to new drugs in acute myeloid leukemia.
Löwenberg B
J Clin Oncol; 2007 Jan; 25(1):1-2. PubMed ID: 17146103
[No Abstract] [Full Text] [Related]
36. New approaches in acute myeloid leukemia.
Blum W; Marcucci G
Best Pract Res Clin Haematol; 2008 Mar; 21(1):29-41. PubMed ID: 18342810
[TBL] [Abstract][Full Text] [Related]
37. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia.
Mayer RJ
Semin Oncol; 1987 Dec; 14(4):384-96. PubMed ID: 3321443
[No Abstract] [Full Text] [Related]
38. Acute promyelocytic leukemia: recent advances in diagnosis and management.
Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
[TBL] [Abstract][Full Text] [Related]
39. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
Amadori S; Stasi R
Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
[TBL] [Abstract][Full Text] [Related]
40. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Short NJ; Ravandi F
Expert Rev Hematol; 2016 Jun; 9(6):529-34. PubMed ID: 27158854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
